DavidMorgan

David Morgan, Ph.D.

Distinguished Professor, College Of Medicine Molecular Pharmacology & Physiology

Division Director, College Of Medicine Molecular Pharmacology & Physiology

Director, Signature Program in Neuroscience, USF College of Medicine

Distinguished Professor, Dept. of Molec. Pharm & Physiol, University of South Florida

CEO / Director, Byrd Alzheimer Institute, USF College of Medicine

Contact Info Alzheimer Institute
4001 E. Fletcher Ave
Tampa, FL 33613

Academic Email: scientist.dave@gmail.com

Academic Phone: (813) 974-3949

View My C.V.

Education

  • PHD, Neurobiology, Northwestern University, 1981
  • M.S., Neurobiology, Northwestern University, 1978
  • B.A., Philosophy/Psychology, Northwestern University, 1974

Academic Philosophy

"When exploring the truly unknown, one must proceed blindly. New knowledge is a process of random variation and selective retention."

Interdisciplinary and Emerging Signature Programs

  • Allergy, Immunology & Infectious Disease
  • Biomedical Engineering & Nanomedicine
  • Metabolic Regulation and Disorders
  • Neurodegenerative Disease
  • Neuroscience
  • Neuroscience

Research Interests

  • Fundamental changes in aging brain and age related neurological disorders
  • Role of astrocytes and microglial cells in the brains reaction to injury .
  • Development of animal models for age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's disease
  • Identification of the mechanisms leading to neuron loss in neurodegenerative disorders.
  • Testing of therapeutic agents addressing the mechanisms of neurotoxicity in age-related neurodegenerative disorders

Memberships

  • ASNTR (Councilor, 1998 - Present)
  • Society for Neuroscience (member, 1980 - Present)
  • Researchers Against Alzheimer's (Lead Representative, 2012 - Present)

Recent Publications

  • Morgan D See CV Many. 1(1) : 1, 2014.
  • Selenica, ML.Brownlow, M.Jimenez, JP.Lee, DC.Pena, G.Dickey, CA.Gordon, MN.Morgan, D. Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neuro-degenerative diseases. 11(4) : 165-81, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22796753
  • Nash, KR.Lee, DC.Hunt, JB.Morganti, JM.Selenica, ML.Moran, P.Reid, P.Brownlow, M.Guang-Yu Yang, C.Savalia, M.Gemma, C.Bickford, PC.Gordon, MN.Morgan, D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of aging. 34(6) : 1540-8, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23332170
  • Lee, DC.Rizer, J.Hunt, JB.Selenica, ML.Gordon, MN.Morgan, D. Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathology and applied neurobiology. 39(1) : 69-85, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23171029
  • Lee, DC.Ruiz, CR.Lebson, L.Selenica, ML.Rizer, J.Hunt, JB.Rojiani, R.Reid, P.Kammath, S.Nash, K.Dickey, CA.Gordon, M.Morgan, D. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of aging. 34(6) : 1610-20, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23481567
  • Carty, N.Nash, KR.Brownlow, M.Cruite, D.Wilcock, D.Selenica, ML.Lee, DC.Gordon, MN.Morgan, D. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PloS one. 8(3) : e59626, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23555730
  • Selenica, ML.Alvarez, JA.Nash, KR.Lee, DC.Cao, C.Lin, X.Reid, P.Mouton, PR.Morgan, D.Gordon, MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of neuroinflammation. 10: 86, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23866683
  • Brownlow, ML.Benner, L.D'Agostino, D.Gordon, MN.Morgan, D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PloS one. 8(9) : e75713, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24069439
  • Zhu, Y.Obregon, D.Hou, H.Giunta, B.Ehrhart, J.Fernandez, F.Mori, T.Nikolic, W.Zhao, Y.Morgan, D.Town, T.Tan, J. Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. Journal of cellular and molecular medicine. 15(2) : 327-38, 2011. http://www.ncbi.nlm.nih.gov/pubmed/19900216
  • Morgan, D. Immunotherapy for Alzheimer's disease. Journal of internal medicine. 269(1) : 54-63, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21158978
  • Carty, N.Lee, D.Dickey, C.Ceballos-Diaz, C.Jansen-West, K.Golde, TE.Gordon, MN.Morgan, D.Nash, K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1) : 144-53, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20951738
  • Li, QY.Gordon, MN.Chackerian, B.Alamed, J.Ugen, KE.Morgan, D. Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 5(1) : 133-42, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20066498
  • Ajmo, JM.Bailey, LA.Howell, MD.Cortez, LK.Pennypacker, KR.Mehta, HN.Morgan, D.Gordon, MN.Gottschall, PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. Journal of neurochemistry. 113(3) : 784-95, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20180882
  • Lebson, L.Nash, K.Kamath, S.Herber, D.Carty, N.Lee, DC.Li, Q.Szekeres, K.Jinwal, U.Koren, J.Dickey, CA.Gottschall, PE.Morgan, D.Gordon, MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29) : 9651-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20660248
  • Lee, DC.Rizer, J.Selenica, ML.Reid, P.Kraft, C.Johnson, A.Blair, L.Gordon, MN.Dickey, CA.Morgan, D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of neuroinflammation. 7: 56, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20846376
  • Jinwal, UK.Miyata, Y.Koren, J.Jones, JR.Trotter, JH.Chang, L.O'Leary, J.Morgan, D.Lee, DC.Shults, CL.Rousaki, A.Weeber, EJ.Zuiderweg, ER.Gestwicki, JE.Dickey, CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(39) : 12079-88, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19793966
  • Morgan, D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS & neurological disorders drug targets. 8(1) : 7-15, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19275633
  • Lord, A.Englund, H.Söderberg, L.Tucker, S.Clausen, F.Hillered, L.Gordon, M.Morgan, D.Lannfelt, L.Pettersson, FE.Nilsson, LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The FEBS journal. 276(4) : 995-1006, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19215301
  • Morgan, D.Landreth, G.Bickford, P. The promise and perils of an Alzheimer disease vaccine: a video debate. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 4(1) : 1-3, 2009. http://www.ncbi.nlm.nih.gov/pubmed/18946741
  • Karlnoski, RA.Rosenthal, A.Kobayashi, D.Pons, J.Alamed, J.Mercer, M.Li, Q.Gordon, MN.Gottschall, PE.Morgan, D. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(15) : 4964-71, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19369565
  • Dickey, C.Kraft, C.Jinwal, U.Koren, J.Johnson, A.Anderson, L.Lebson, L.Lee, D.Dickson, D.de Silva, R.Binder, LI.Morgan, D.Lewis, J. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. The American journal of pathology. 174(1) : 228-38, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19074615
  • Carty, NC.Nash, K.Lee, D.Mercer, M.Gottschall, PE.Meyers, C.Muzyczka, N.Gordon, MN.Morgan, D. Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Abeta Deposits in APP + PS1 Transgenic Mice. Molecular therapy : the journal of the American Society of Gene Therapy. , 2008. http://www.ncbi.nlm.nih.gov/pubmed/18665160
  • Morgan, D.Munireddy, S.Alamed, J.DeLeon, J.Diamond, DM.Bickford, P.Hutton, M.Lewis, J.McGowan, E.Gordon, MN. Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. Journal of Alzheimer's disease : JAD. 15(4) : 605-14, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19096159
  • Li, Q.Gordon, M.Etienne, MA.Hammer, RP.Morgan, D. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell transplantation. 17(4) : 397-408, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18522242
  • Karlnoski, RA.Rosenthal, A.Alamed, J.Ronan, V.Gordon, MN.Gottschall, PE.Grimm, J.Pons, J.Morgan, D. Deglycosylated Anti-Abeta Antibody Dose-Response Effects on Pathology and Memory in APP Transgenic Mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. , 2008. http://www.ncbi.nlm.nih.gov/pubmed/18607758
  • Dickey, CA.Koren, J.Zhang, YJ.Xu, YF.Jinwal, UK.Birnbaum, MJ.Monks, B.Sun, M.Cheng, JQ.Patterson, C.Bailey, RM.Dunmore, J.Soresh, S.Leon, C.Morgan, D.Petrucelli, L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America. 105(9) : 3622-7, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18292230
  • Morgan, D.Gordon, MN. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behavioral neuroscience. 122(3) : 730-2, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18513144
  • Herber, DL.Mercer, M.Roth, LM.Symmonds, K.Maloney, J.Wilson, N.Freeman, MJ.Morgan, D.Gordon, MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2(2) : 222-31, 2007. http://www.ncbi.nlm.nih.gov/pubmed/18040847
  • Li, Q.Gordon, M.Cao, C.Ugen, KE.Morgan, D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC neuroscience. 8: 22, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17374155
  • Morgan, D. Amyloid, memory and neurogenesis. Experimental neurology. 205(2) : 330-5, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17445801
  • Nikolic, WV.Bai, Y.Obregon, D.Hou, H.Mori, T.Zeng, J.Ehrhart, J.Shytle, RD.Giunta, B.Morgan, D.Town, T.Tan, J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proceedings of the National Academy of Sciences of the United States of America. 104(7) : 2507-12, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17264212
  • Wilcock, DM.Jantzen, PT.Li, Q.Morgan, D.Gordon, MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 144(3) : 950-60, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17137722
  • Karlnoski, R.Wilcock, D.Dickey, C.Ronan, V.Gordon, MN.Zhang, W.Morgan, D.Taglialatela, G. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of disease. 25(1) : 179-88, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17067805
  • Herber, DL.Maloney, JL.Roth, LM.Freeman, MJ.Morgan, D.Gordon, MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia. 53(4) : 382-91, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16288481
  • Carty, NC.Wilcock, DM.Rosenthal, A.Grimm, J.Pons, J.Ronan, V.Gottschall, PE.Gordon, MN.Morgan, D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of neuroinflammation. 3: 11, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16686956
  • Wilcock, DM.Gordon, MN.Morgan, D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature protocols. 1(3) : 1591-5, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17406451
  • Wilcock, DM.Alamed, J.Gottschall, PE.Grimm, J.Rosenthal, A.Pons, J.Ronan, V.Symmonds, K.Gordon, MN.Morgan, D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(20) : 5340-6, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16707786
  • Morgan, D. Immunotherapy for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 9(3 Suppl) : 425-32, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16914881
  • Morgan, D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochemistry international. 49(2) : 190-4, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16740342
  • Morgan, D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neuro-degenerative diseases. 2(5) : 261-6, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16909007
  • Rezai-Zadeh, K.Shytle, D.Sun, N.Mori, T.Hou, H.Jeanniton, D.Ehrhart, J.Townsend, K.Zeng, J.Morgan, D.Hardy, J.Town, T.Tan, J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(38) : 8807-14, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16177050
  • Dickey, CA.Gordon, MN.Wilcock, DM.Herber, DL.Freeman, MJ.Morgan, D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC neuroscience. 6(1) : 7, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15689237
  • Morgan, D.Gordon, MN.Tan, J.Wilcock, D.Rojiani, AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of neuropathology and experimental neurology. 64(9) : 743-53, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16141783
  • Townsend, KP.Town, T.Mori, T.Lue, LF.Shytle, D.Sanberg, PR.Morgan, D.Fernandez, F.Flavell, RA.Tan, J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. European journal of immunology. 35(3) : 901-10, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15688347
  • Garcia, MF.Gordon, MN.Hutton, M.Lewis, J.McGowan, E.Dickey, CA.Morgan, D.Arendash, GW. The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport. 15(1) : 73-7, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15106834
  • Wilcock, DM.Munireddy, SK.Rosenthal, A.Ugen, KE.Gordon, MN.Morgan, D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiology of disease. 15(1) : 11-20, 2004. http://www.ncbi.nlm.nih.gov/pubmed/14751766
  • Dickey, CA.Gordon, MN.Mason, JE.Wilson, NJ.Diamond, DM.Guzowski, JF.Morgan, D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. Journal of neurochemistry. 88(2) : 434-42, 2004. http://www.ncbi.nlm.nih.gov/pubmed/14690531
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Levkowitz, G.Subbarao, S.Alamed, J.Wilson, D.Wilson, N.Freeman, MJ.Gordon, MN.Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24(27) : 6144-51, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15240806
  • Dickey, CA.De Mesquita, DD.Morgan, D.Pennypacker, KR. Induction of memory-associated immediate early genes by nerve growth factor in rat primary cortical neurons and differentiated mouse Neuro2A cells. Neuroscience letters. 366(1) : 10-4, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15265580
  • Townsend, KP.Shytle, DR.Bai, Y.San, N.Zeng, J.Freeman, M.Mori, T.Fernandez, F.Morgan, D.Sanberg, P.Tan, J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. Journal of neuroscience research. 78(2) : 167-76, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15378516
  • Herber, DL.Severance, EG.Cuevas, J.Morgan, D.Gordon, MN. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 52(10) : 1367-76, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15385583
  • Herber, DL.Roth, LM.Wilson, D.Wilson, N.Mason, JE.Morgan, D.Gordon, MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Experimental neurology. 190(1) : 245-53, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15473997
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Subbarao, S.Freeman, MJ.Gordon, MN.Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of neuroinflammation. 1(1) : 24, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15588287
  • Morgan, D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochemical research. 28(7) : 1029-34, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12737527
  • Austin, L.Arendash, GW.Gordon, MN.Diamond, DM.DiCarlo, G.Dickey, C.Ugen, K.Morgan, D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behavioral neuroscience. 117(3) : 478-84, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12802876
  • Kassed, CA.Butler, TL.Navidomskis, MT.Gordon, MN.Morgan, D.Pennypacker, KR. Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury. Brain research. Molecular brain research. 110(1) : 152-7, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12573544
  • Dickey, CA.Loring, JF.Montgomery, J.Gordon, MN.Eastman, PS.Morgan, D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(12) : 5219-26, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12832546
  • Morgan, D. Antibody therapy for Alzheimer's disease. Expert review of vaccines. 2(1) : 53-9, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12901597
  • Wilcock, DM.DiCarlo, G.Henderson, D.Jackson, J.Clarke, K.Ugen, KE.Gordon, MN.Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(9) : 3745-51, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12736345
  • Gordon, MN.Holcomb, LA.Jantzen, PT.DiCarlo, G.Wilcock, D.Boyett, KW.Connor, K.Melachrino, J.O'Callaghan, JP.Morgan, D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental neurology. 173(2) : 183-95, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11822882
  • Morgan, D.Keller, RK. What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 4(3) : 257-60, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12226546
  • Jantzen, PT.Connor, KE.DiCarlo, G.Wenk, GL.Wallace, JL.Rojiani, AM.Coppola, D.Morgan, D.Gordon, MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(6) : 2246-54, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11896164
  • Arendash, GW.King, DL.Gordon, MN.Morgan, D.Hatcher, JM.Hope, CE.Diamond, DM. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain research. 891(1-2) : 42-53, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11164808
  • Gordon, MN.King, DL.Diamond, DM.Jantzen, PT.Boyett, KV.Hope, CE.Hatcher, JM.DiCarlo, G.Gottschall, WP.Morgan, D.Arendash, GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of aging. 22(3) : 377-85, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11378242
  • Morgan, D.Diamond, DM.Gottschall, PE.Ugen, KE.Dickey, C.Hardy, J.Duff, K.Jantzen, P.DiCarlo, G.Wilcock, D.Connor, K.Hatcher, J.Hope, C.Gordon, M.Arendash, GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815) : 982-5, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11140686
  • Holcomb, L.Gordon, MN.McGowan, E.Yu, X.Benkovic, S.Jantzen, P.Wright, K.Saad, I.Mueller, R.Morgan, D.Sanders, S.Zehr, C.O'Campo, K.Hardy, J.Prada, CM.Eckman, C.Younkin, S.Hsiao, K.Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature medicine. 4(1) : 97-100, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9427614
  • Duff, K.Eckman, C.Zehr, C.Yu, X.Prada, CM.Perez-tur, J.Hutton, M.Buee, L.Harigaya, Y.Yager, D.Morgan, D.Gordon, MN.Holcomb, L.Refolo, L.Zenk, B.Hardy, J.Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383(6602) : 710-3, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8878479

Awards/Honors

  • Medical Hero Award (Temple Terrace Chamber of Commerce - 2012)
  • Distinguished Health Professor (University of South Florida - 2010)
  • USF President's Award for Faculty Excellence (University of South Florida - 2002)
  • Established Investigator Award (American Heart Association - 1989)